Helen Cox

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5524786/publications.pdf

Version: 2024-02-01

99 papers	7,058 citations	76326 40 h-index	60623 81 g-index
105 all docs	105 docs citations	105 times ranked	6878 citing authors

#	Article	IF	Citations
1	Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet, The, 2011, 377, 1495-1505.	13.7	902
2	Tuberculosis. Lancet, The, 2019, 393, 1642-1656.	13.7	523
3	Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nature Genetics, 2015, 47, 242-249.	21.4	466
4	Multidrug Resistant Pulmonary Tuberculosis Treatment Regimens and Patient Outcomes: An Individual Patient Data Meta-analysis of 9,153 Patients. PLoS Medicine, 2012, 9, e1001300.	8.4	430
5	Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. European Respiratory Journal, 2013, 42, 156-168.	6.7	346
6	Building a tuberculosis-free world: The Lancet Commission on tuberculosis. Lancet, The, 2019, 393, 1331-1384.	13.7	257
7	Drug-resistant tuberculosis: time for visionary political leadership. Lancet Infectious Diseases, The, 2013, 13, 529-539.	9.1	243
8	Xpert MTB/RIF versus sputum microscopy as the initial diagnostic test for tuberculosis: a cluster-randomised trial embedded in South African roll-out of Xpert MTB/RIF. The Lancet Global Health, 2015, 3, e450-e457.	6.3	179
9	Tuberculosis Diagnostics and Biomarkers: Needs, Challenges, Recent Advances, and Opportunities. Journal of Infectious Diseases, 2012, 205, S147-S158.	4.0	154
10	Drug-Resistant Tuberculosisâ€"Current Dilemmas, Unanswered Questions, Challenges, and Priority Needs. Journal of Infectious Diseases, 2012, 205, S228-S240.	4.0	140
11	Genomic Diversity among Drug Sensitive and Multidrug Resistant Isolates of Mycobacterium tuberculosis with Identical DNA Fingerprints. PLoS ONE, 2009, 4, e7407.	2.5	128
12	Linezolid for the treatment of complicated drug-resistant tuberculosis: a systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2012, 16, 447-454.	1.2	123
13	Drug-resistant tuberculosis: challenges and opportunities for diagnosis and treatment. Current Opinion in Pharmacology, 2018, 42, 7-15.	3.5	121
14	Strategies for reducing treatment default in drug-resistant tuberculosis: systematic review and meta-analysis [Review article]. International Journal of Tuberculosis and Lung Disease, 2013, 17, 299-307.	1.2	119
15	Impact of Xpert MTB/RIF for TB Diagnosis in a Primary Care Clinic with High TB and HIV Prevalence in South Africa: A Pragmatic Randomised Trial. PLoS Medicine, 2014, 11, e1001760.	8.4	118
16	Whole Genome Sequencing Reveals Complex Evolution Patterns of Multidrug-Resistant Mycobacterium tuberculosis Beijing Strains in Patients. PLoS ONE, 2013, 8, e82551.	2.5	117
17	Outcomes of clofazimine for the treatment of drug-resistant tuberculosis: a systematic review and meta-analysis. Journal of Antimicrobial Chemotherapy, 2013, 68, 284-293.	3.0	116
18	Treatment Outcomes of Patients With Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis According to Drug Susceptibility Testing to First- and Second-line Drugs: An Individual Patient Data Meta-analysis. Clinical Infectious Diseases, 2014, 59, 1364-1374.	5.8	116

#	Article	IF	Citations
19	Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study. Lancet Infectious Diseases, The, 2018, 18, 536-544.	9.1	106
20	Preventive Therapy for Child Contacts of Multidrug-Resistant Tuberculosis: A Prospective Cohort Study. Clinical Infectious Diseases, 2013, 57, 1676-1684.	5.8	101
21	Tuberculosis Recurrence and Mortality after Successful Treatment: Impact of Drug Resistance. PLoS Medicine, 2006, 3, e384.	8.4	100
22	Compensatory evolution drives multidrug-resistant tuberculosis in Central Asia. ELife, 2018, 7, .	6.0	93
23	Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. International Journal of Tuberculosis and Lung Disease, 2014, 18, 441-448.	1.2	89
24	Sequence Analyses of Just Four Genes To Detect Extensively Drug-Resistant Mycobacterium tuberculosis Strains in Multidrug-Resistant Tuberculosis Patients Undergoing Treatment. Antimicrobial Agents and Chemotherapy, 2009, 53, 3353-3356.	3.2	88
25	Multidrug-Resistant Tuberculosis Treatment Outcomes in Karakalpakstan, Uzbekistan: Treatment Complexity and XDR-TB among Treatment Failures. PLoS ONE, 2007, 2, e1126.	2.5	84
26	Delays and loss to follow-up before treatment of drug-resistant tuberculosis following implementation of Xpert MTB/RIF in South Africa: A retrospective cohort study. PLoS Medicine, 2017, 14, e1002238.	8.4	81
27	Comparison of different treatments for isoniazid-resistant tuberculosis: an individual patient data meta-analysis. Lancet Respiratory Medicine,the, 2018, 6, 265-275.	10.7	80
28	Adverse Events among HIV/MDR-TB Co-Infected Patients Receiving Antiretroviral and Second Line Anti-TB Treatment in Mumbai, India. PLoS ONE, 2012, 7, e40781.	2.5	80
29	embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis isolates without embB306 mutation. Journal of Antimicrobial Chemotherapy, 2010, 65, 1359-1367.	3.0	76
30	Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa. PLoS ONE, 2010, 5, e13901.	2.5	71
31	Ambulatory Multi-Drug Resistant Tuberculosis Treatment Outcomes in a Cohort of HIV-Infected Patients in a Slum Setting in Mumbai, India. PLoS ONE, 2011, 6, e28066.	2.5	71
32	Risk of Acquired Drug Resistance during Short-Course Directly Observed Treatment of Tuberculosis in an Area with High Levels of Drug Resistance. Clinical Infectious Diseases, 2007, 44, 1421-1427.	5.8	68
33	Infection Control for Drug-Resistant Tuberculosis: Early Diagnosis and Treatment Is the Key: Table 1.. Clinical Infectious Diseases, 2016, 62, S238-S243.	5.8	60
34	Emergence of Extensive Drug Resistance during Treatment for Multidrug-Resistant Tuberculosis. New England Journal of Medicine, 2008, 359, 2398-2400.	27.0	57
35	Population Structure of Mixed Mycobacterium tuberculosis Infection Is Strain Genotype and Culture Medium Dependent. PLoS ONE, 2013, 8, e70178.	2.5	57
36	A systematic review and meta-analysis of the efficacy and safety ofN-acetylcysteine in preventing aminoglycoside-induced ototoxicity: implications for the treatment of multidrug-resistant TB. Thorax, 2015, 70, 1070-1077.	5.6	54

#	Article	IF	Citations
37	Effect of Xpert MTB/RIF on clinical outcomes in routine care settings: individual patient data meta-analysis. The Lancet Global Health, 2019, 7, e191-e199.	6.3	53
38	Recent controversies about <scp>MDR</scp> and <scp>XDRâ€TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDRâ€TB</scp> regimen and bedaquiline for all with <scp>MDRâ€TB</scp>?. Respirology, 2018, 23, 36-45.	2.3	52
39	Impact of reduced hospitalisation on the cost of treatment for drug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 2015, 19, 172-178.	1.2	48
40	QTc prolongation and treatment of multidrug-resistant tuberculosis. International Journal of Tuberculosis and Lung Disease, 2015, 19, 385-391.	1.2	46
41	Drug susceptibility testing and mortality in patients treated for tuberculosis in high-burden countries: a multicentre cohort study. Lancet Infectious Diseases, The, 2019, 19, 298-307.	9.1	45
42	Patients' costs associated with seeking and accessing treatment for drug-resistant tuberculosis in South Africa. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1513-1519.	1.2	41
43	Delamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africa. European Respiratory Journal, 2018, 51, 1800017.	6.7	39
44	Access to new medications for the treatment of drug-resistant tuberculosis: Patient, provider and community perspectives. International Journal of Infectious Diseases, 2015, 32, 56-60.	3.3	36
45	Precision medicine for drug-resistant tuberculosis in high-burden countries: is individualised treatment desirable and feasible?. Lancet Infectious Diseases, The, 2018, 18, e282-e287.	9.1	35
46	â€œA very humiliating illnessâ€• a qualitative study of patient-centered Care for Rifampicin-Resistant Tuberculosis in South Africa. BMC Public Health, 2020, 20, 76.	2.9	34
47	Epidemiology of Drug-Resistant Tuberculosis. Advances in Experimental Medicine and Biology, 2017, 1019, 209-220.	1.6	32
48	Monoaminergic Neuronal Activity in Subcortical Brain Regions in Essential Hypertension. Blood Pressure, 1994, 3, 55-66.	1.5	31
49	Cost per patient of treatment for rifampicinâ€resistant tuberculosis in a communityâ€based programme in Khayelitsha, South Africa. Tropical Medicine and International Health, 2015, 20, 1337-1345.	2.3	31
50	Tuberculosis ethambutol resistance: Concordance between phenotypic and genotypic test results. Tuberculosis, 2009, 89, 448-452.	1.9	30
51	Multidrug-resistant tuberculosis treatment failure detection depends on monitoring interval and microbiological method. European Respiratory Journal, 2016, 48, 1160-1170.	6.7	27
52	Wind-Driven Roof Turbines: A Novel Way to Improve Ventilation for TB Infection Control in Health Facilities. PLoS ONE, 2012, 7, e29589.	2.5	27
53	Loss from Treatment for Drug Resistant Tuberculosis: Risk Factors and Patient Outcomes in a Community-Based Program in Khayelitsha, South Africa. PLoS ONE, 2015, 10, e0118919.	2.5	26
54	Clinical deterioration during antituberculosis treatment in Africa: Incidence, causes and risk factors. BMC Infectious Diseases, 2010, 10, 83.	2.9	24

#	Article	IF	Citations
55	Linezolid for multidrug-resistant tuberculosis in HIV-infected and -uninfected patients. European Respiratory Journal, 2015, 46, 271-274.	6.7	24
56	Programmatic treatment outcomes in HIV-infected and uninfected drug-resistant TB patients in Khayelitsha, South Africa. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2015, 109, 425-432.	1.8	20
57	Group 5 drugs for multidrug-resistant tuberculosis: individual patient data meta-analysis. European Respiratory Journal, 2017, 49, 1600993.	6.7	20
58	Oral Swab Specimens Tested With Xpert MTB/RIF Ultra Assay for Diagnosis of Pulmonary Tuberculosis in Children: A Diagnostic Accuracy Study. Clinical Infectious Diseases, 2022, 75, 2145-2152.	5.8	20
59	Outbreak of multidrug-resistant tuberculosis on Daru Island. Lancet Respiratory Medicine,the, 2016, 4, 347-349.	10.7	17
60	First Molecular Epidemiology Study of Mycobacterium tuberculosis in Kiribati. PLoS ONE, 2013, 8, e55423.	2.5	16
61	Effect of multidrug resistance on global tuberculosis control. Lancet, The, 2003, 362, 1858-1859.	13.7	15
62	Compassionate and optimum use of new tuberculosis drugs. Lancet Infectious Diseases, The, 2015, 15, 1131.	9.1	15
63	The Coming of Age of Drug-Susceptibility Testing for Tuberculosis. New England Journal of Medicine, 2018, 379, 1474-1475.	27.0	15
64	The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bulletin of the World Health Organization, 2015, 93, 491-497.	3.3	14
65	Whole-Genome Sequencing Has the Potential To Improve Treatment for Rifampicin-Resistant Tuberculosis in High-Burden Settings: a Retrospective Cohort Study. Journal of Clinical Microbiology, 2022, 60, jcm0236221.	3.9	14
66	Mineralocorticoid Induced Hypertension and Noradrenaline Spillover In Man. Clinical and Experimental Hypertension, 1994, 16, 147-161.	1.3	13
67	Decentralisation of multidrug-resistant-tuberculosis care and management. Lancet Infectious Diseases, The, 2013, 13, 644-646.	9.1	12
68	Time to ART Initiation among Patients Treated for Rifampicin-Resistant Tuberculosis in Khayelitsha, South Africa: Impact on Mortality and Treatment Success. PLoS ONE, 2015, 10, e0142873.	2.5	12
69	Rational use of moxifloxacin for tuberculosis treatment. Lancet Infectious Diseases, The, 2011, 11, 259-260.	9.1	11
70	Are we really that good at treating tuberculosis?. Lancet Infectious Diseases, The, 2009, 9, 138-139.	9.1	10
71	Multidrug-Resistant TB: Implementing the Right to Health through the Right to Enjoy the Benefits of Scientific Progress. Health and Human Rights, 2016, 18, 25-41.	1.3	10
72	Tuberculosis eradication: renewed commitment and global investment required. Lancet Infectious Diseases, The, 2018, 18, 228-229.	9.1	9

#	Article	IF	Citations
73	The STREAM trial: missed opportunities and lessons for future clinical trials. Lancet Infectious Diseases, The, 2019, 19, 351-353.	9.1	9
74	Potential contribution of HIV during first-line tuberculosis treatment to subsequent rifampicin-monoresistant tuberculosis and acquired tuberculosis drug resistance in South Africa: a retrospective molecular epidemiology study. Lancet Microbe, The, 2021, 2, e584-e593.	7.3	9
75	XDR tuberculosis can be cured with aggressive treatment. Lancet, The, 2008, 372, 1363-1365.	13.7	8
76	â€œThis is not my bodyâ€: Therapeutic experiences and post-treatment health of people with rifampicin-resistant tuberculosis. PLoS ONE, 2021, 16, e0251482.	2.5	8
77	Linezolid for multidrug-resistant tuberculosis. Lancet Infectious Diseases, The, 2013, 13, 16.	9.1	7
78	HIV Coinfection Is Associated with Low-Fitness rpoB Variants in Rifampicin-Resistant Mycobacterium tuberculosis. Antimicrobial Agents and Chemotherapy, 2020, 64, .	3.2	7
79	Rifampicin-Monoresistant Tuberculosis Is Not the Same as Multidrug-Resistant Tuberculosis: a Descriptive Study from Khayelitsha, South Africa. Antimicrobial Agents and Chemotherapy, 2021, 65, e0036421.	3.2	7
80	Outcomes in Adolescents Undergoing Treatment for Drug-resistant Tuberculosis in Cape Town, South Africa, 2008-2013. Archives of Pediatric Infectious Diseases, 2014, 2, .	0.3	7
81	Sanatoria for drug-resistant tuberculosis: an outdated response. Lancet, The, 2012, 379, 2148.	13.7	6
82	Preventing drug-resistant tuberculosis transmission. Lancet Infectious Diseases, The, 2020, 20, 157-158.	9.1	5
83	â€˜We had to manage what we had on hand, in whatever way we couldâ€™: adaptive responses in policy for decentralized drug-resistant tuberculosis care in South Africa. Health Policy and Planning, 2021, 36, 249-259.	2.7	5
84	To treat or not to treat? Implementation of DOTS in Central Asia. Lancet, The, 2003, 361, 714-715.	13.7	4
85	Household screening and multidrug-resistant tuberculosis. Lancet, The, 2011, 377, 103-104.	13.7	4
86	The benefits and risks of mathematical modelling in tuberculosis. International Journal of Tuberculosis and Lung Disease, 2014, 18, 507-507.	1.2	4
87	Prevention of hearing loss in patients with multidrug-resistant tuberculosis. Lancet, The, 2017, 390, 934.	13.7	4
88	Linezolid in drug-resistant tuberculosis: haste makes waste. European Respiratory Journal, 2015, 46, 1844-1846.	6.7	3
89	Tuberculosis trends in the Pacific: 2000-2006. Pacific Health Dialog: A Publication of the Pacific Basin Officers Training Program and the Fiji School of Medicine, 2010, 16, 157-71.	0.2	3
90	Extensively drug-resistant tuberculosis in South Africa. Lancet, The, 2010, 376, 681.	13.7	2

#	Article	IF	Citations
91	MDR tuberculosis and non-compliance with therapy. Lancet Infectious Diseases, The, 2012, 12, 178.	9.1	2
92	Moxifloxacin for tuberculosis â€“ Authors' reply. Lancet Infectious Diseases, The, 2012, 12, 177-178.	9.1	2
93	The scourge of tuberculosis and anti-tuberculosis drug resistance in Eastern Europe. Public Health Action, 2014, 4, 1-2.	1.2	2
94	Correspondence regarding â€œDelamanid for rifampicin-resistant tuberculosis: a retrospective study from South Africaâ€. European Respiratory Journal, 2020, 56, 2000837.	6.7	2
95	Better treatment of XDR tuberculosis needed in South Africa. Lancet, The, 2014, 384, 581-582.	13.7	1
96	Building resilience needs to be central to treating drug-resistant tuberculosis. The Lancet Global Health, 2021, 9, e381-e382.	6.3	1
97	Treatment Response in Pediatric Pulmonary Tuberculosisâ€”A Prospective Longitudinal Study. Journal of the Pediatric Infectious Diseases Society, 2022, 11, 329-336.	1.3	1
98	In reply. QTc prolongation and delamanid: access and safety. International Journal of Tuberculosis and Lung Disease, 2015, 19, 1262-1263.	1.2	0
99	The incalculable costs of tuberculosis. The Lancet Global Health, 2021, 9, e1337-e1338.	6.3	0